NICE Backing For Procolaran In CHF May Prove Lucrative For Servier

If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.

There is finally some good news for Servier SA on the European front, following final guidance for the company’s heart rate lowering agent Procoralan (ivabradine) from England’s National Institute for Health and Clinical Excellence. With the company’s finances set to take a significant hit within the next few years, Servier must be hoping that NICE’s positive stance on the new indication of chronic heart failure for Procolaran eventually will amount to something of a goldmine.

NICE’s thumbs-up means that Procolaran will be used in the NHS for chronic heart failure, but only after optimal standard therapy with ACE inhibitors, beta-blockers and aldosterone antagonists, and after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

EMA Rejects Treatments For Pediatric Myopia & CTCL

 
• By 

EU marketing applications for drugs aimed at slowing myopia progression in children and for treating cutaneous T-cell lymphoma have been turned down by the European Medicines Agency.

More from Geography

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By 

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.